Maurer Katie, Weir Jackson A, Nagler Adi, Haradhvala Nicholas J, Bharadwaj Hariharan, Shapiro Jacob, Alakwe Somkene, Kumar Vipin, Waller Brianna, McDonough Mikaela, Dela Cruz Jamie, Luna Loida, Lin Emma, Gong Linsey, Gong Qiyu, Borji Mehdi, Michaels Phillip D, Laubach Jacob P, Pinkus Geraldine, Getz Gad, Wu Catherine J, Chen Fei, Jacobson Caron
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Harvard Medical School, Boston, MA, US.
Nat Commun. 2025 Aug 12;16(1):7462. doi: 10.1038/s41467-025-62709-7.
Reports of secondary malignancies after chimeric antigen receptor (CAR)-T and possible CAR-T derived malignant transformation necessitate caution. Here we describe a patient with diffuse large B-cell lymphoma who developed new lymphadenopathy 2.5 years after CAR-T in the context of COVID-19 infection with histopathologic features consistent with T-cell lymphoma (TCL). Deep molecular interrogation with genomic sequencing and single-cell spatial transcriptomics reveals a highly proliferative clonal T-cell population co-expressing CD4 and CD8 with biallelic TCR rearrangement and no evidence of the CAR construct. The expanded clonotype displayed T follicular helper (TFH) cell transcriptomic programs and occupies immune-excluded spatial niches within the lymph node, supportive of TFH-like neoplastic T cell behavior. Remarkably, the lymphadenopathy spontaneously resolved on interval imaging. Our data underscore the need for better understanding of post-CAR-T clonal T-cell lymphoproliferative disorders to avoid unnecessary treatment and higher specificity in diagnostic methods for TCL.
嵌合抗原受体(CAR)-T细胞治疗后出现继发性恶性肿瘤以及可能由CAR-T细胞引发的恶性转化的报告,警示我们需谨慎对待。在此,我们描述了一名弥漫性大B细胞淋巴瘤患者,在接受CAR-T细胞治疗2.5年后,于COVID-19感染背景下出现了新的淋巴结病,其组织病理学特征与T细胞淋巴瘤(TCL)相符。通过基因组测序和单细胞空间转录组学进行的深度分子分析显示,存在一个高度增殖的克隆性T细胞群体,该群体共表达CD4和CD8,具有双等位基因TCR重排,且未发现CAR构建体的证据。扩增的克隆型显示出T滤泡辅助(TFH)细胞转录组程序,并占据淋巴结内免疫排斥的空间龛位,支持TFH样肿瘤性T细胞行为。值得注意的是,淋巴结病在间隔期影像学检查中自发消退。我们的数据强调了更好地理解CAR-T细胞治疗后克隆性T细胞淋巴增殖性疾病的必要性,以避免不必要的治疗,并提高TCL诊断方法的特异性。